JP6676661B2 - ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物 - Google Patents
ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物 Download PDFInfo
- Publication number
- JP6676661B2 JP6676661B2 JP2017562353A JP2017562353A JP6676661B2 JP 6676661 B2 JP6676661 B2 JP 6676661B2 JP 2017562353 A JP2017562353 A JP 2017562353A JP 2017562353 A JP2017562353 A JP 2017562353A JP 6676661 B2 JP6676661 B2 JP 6676661B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- amino acid
- fusion
- fusion protein
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 21
- 210000004392 genitalia Anatomy 0.000 title claims description 8
- 230000000241 respiratory effect Effects 0.000 title claims description 8
- 208000011580 syndromic disease Diseases 0.000 title claims description 8
- 229960005486 vaccine Drugs 0.000 title description 36
- 201000010099 disease Diseases 0.000 title description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 7
- 241000202347 Porcine circovirus Species 0.000 title 1
- 108091007433 antigens Proteins 0.000 claims description 189
- 102000036639 antigens Human genes 0.000 claims description 189
- 239000000427 antigen Substances 0.000 claims description 187
- 230000004927 fusion Effects 0.000 claims description 68
- 108020001507 fusion proteins Proteins 0.000 claims description 63
- 102000037865 fusion proteins Human genes 0.000 claims description 63
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims description 60
- 101710087110 ORF6 protein Proteins 0.000 claims description 42
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 claims description 29
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 claims description 29
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 claims description 29
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 claims description 29
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 claims description 29
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 claims description 29
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 claims description 29
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 claims description 29
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 claims description 29
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 claims description 29
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 claims description 29
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 claims description 29
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 claims description 29
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 claims description 29
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 claims description 29
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 claims description 29
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 claims description 29
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 claims description 29
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 claims description 29
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 claims description 29
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 claims description 29
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 claims description 29
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 claims description 29
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 claims description 29
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 claims description 29
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 claims description 29
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 claims description 29
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 claims description 28
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 28
- 241001673669 Porcine circovirus 2 Species 0.000 claims description 27
- 230000014759 maintenance of location Effects 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 24
- 230000025308 nuclear transport Effects 0.000 claims description 21
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 20
- 230000005945 translocation Effects 0.000 claims description 19
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 15
- 210000004899 c-terminal region Anatomy 0.000 claims description 14
- 101800003471 Helicase Proteins 0.000 claims description 12
- 101900328733 Porcine reproductive and respiratory syndrome virus Glycoprotein 5 Proteins 0.000 claims description 12
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 11
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 230000008348 humoral response Effects 0.000 claims description 9
- 101800000355 Helicase nsp10 Proteins 0.000 claims description 6
- 101800000933 Non-structural protein 10 Proteins 0.000 claims description 6
- 101800000932 Non-structural protein 11 Proteins 0.000 claims description 6
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims description 6
- 101800001925 Uridylate-specific endoribonuclease nsp11 Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 241000282898 Sus scrofa Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims 4
- 241000699670 Mus sp. Species 0.000 description 20
- 239000012634 fragment Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 229940031626 subunit vaccine Drugs 0.000 description 13
- 241000282887 Suidae Species 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 108010066154 Nuclear Export Signals Proteins 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 101000997105 Mus musculus Nik-related protein kinase Proteins 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 6
- 230000028996 humoral immune response Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- WAXHXZWOUQTVQZ-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-n-propylpropan-2-amine;hydrochloride Chemical compound Cl.CCCNC(C)CC1=CC=C2OCOC2=C1 WAXHXZWOUQTVQZ-UHFFFAOYSA-N 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 101710155913 Major envelope protein Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 101710135104 Uncharacterized protein p6 Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 2
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 230000008350 antigen-specific antibody response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 210000004492 nuclear pore Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000011781 Karyopherins Human genes 0.000 description 1
- 108010062228 Karyopherins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006391 Luria-Bertani Medium Substances 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101000894412 Mycolicibacterium paratuberculosis (strain ATCC BAA-968 / K-10) Bacterioferritin Proteins 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008349 antigen-specific humoral response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/095—Fusion polypeptide containing a localisation/targetting motif containing a nuclear export signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
Description
本発明は、一般にワクチンに関し、より具体的にはサブユニットワクチンに関する。
免疫細胞(T細胞、B細胞、樹状細胞、単球、又はマクロファージなど)に感染するウイルスとしては、ブタ生殖器呼吸器症候群ウイルス(PRRSV)、ブタサーコウイルスタイプII(PCV2)、及びヒト免疫不全ウイルス(HIV)が含まれる。免疫細胞は、免疫化応答を誘発することはできないが、ウイルスを運ぶことができる。これらのウイルスに感染した動物には、他の病原体が容易に感染する可能性がある。ブタ生殖器呼吸器症候群ウイルス(PRRSV)は、毎年、畜産に大きな損失をもたらす。ブタだけでなく、アヒルも同様に、PRRSVに感染する可能性がある。一般に、ウイルスに感染した動物は、顕著な症状を有しないが、感染した動物の免疫性は低下する。このウイルスは、(肺胞及び脾臓中の)マクロファージ、脳ミクログリア及び単球に感染し、感染した動物の血液及び器官に存在し得る。これは、二次感染に起因する体重増加の減少及び死亡率の増加につながる。
一つの態様において、本発明は、ブタ生殖器呼吸器症候群ウイルス(PRRSV)融合タンパク質に関する。このブタ生殖器呼吸器症候群ウイルス(PRRSV)融合タンパク質は、
(a)融合タンパク質のN末端に位置する、抗原提示細胞(APC)結合ドメイン又はCD91レセプター結合ドメイン;
(b)APC結合ドメイン又はCD91レセプター結合ドメインのC末端に位置する、配列番号:4、2、3、又は6と少なくとも90%同一のアミノ酸配列を含む、34−112アミノ酸残基長のトランスロケーションペプチド;
(c)以下の(i)〜(iv)を含む融合抗原;
(i)ブタ生殖器呼吸器症候群ウイルス(PRRSV)ORF7抗原;
(ii)PRRSV ORF1b抗原;
(iii)PRRSV ORF6抗原;及び
(iv)PRRSV ORF5抗原;
(d)融合タンパク質のC末端に位置する、小胞体保持配列;及び
(e)任意選択的に、抗原と小胞体保持配列との間又はトランスロケーションペプチドと抗原との間に位置する、配列番号:13のアミノ酸配列を含む核輸送シグナル
を含み、
ここで、融合抗原が、完全長ORF7、ORF6、ORF5、及びORF1bタンパク質配列を含まない。
(i)本発明のPRRSV融合タンパク質;及び
(ii)ブタサーコウイルスタイプ2(PCV2)融合タンパク質
を含み、
(ii)ブタサーコウイルスタイプ2(PCV2)融合タンパク質が、
(a)融合タンパク質のN末端に位置する、抗原提示細胞(APC)結合ドメイン又はCD91レセプター結合ドメイン;
(b)APC結合ドメイン又はCD91レセプター結合ドメインのC末端に位置する、配列番号:4、2、3、又は6と少なくとも90%同一のアミノ酸配列を含む、34−112アミノ酸残基長のトランスロケーションペプチド;及び
(c)PCV2 ORF2抗原;
(d)融合タンパク質のC末端に位置する、小胞体保持配列;及び
(e)抗原と小胞体保持配列との間又はトランスロケーションペプチドと抗原との間に位置する、配列番号:13のアミノ酸配列を含む核輸送シグナル
を含み、
ここで、PCV2 ORF2抗原が、PCV2 ORF2タンパク質のC末端部アミノ酸配列を含み、PCV2融合タンパク質が、PCV2 ORF2タンパク質のN末端部アミノ酸配列を含まない。
本発明は、以下の実施例においてより具体的に説明されている。これらの実施例は、単なる例示であることが意図される。なぜなら、実施例における多数の改変及び変更が当業者には明らかであるためである。本発明の様々な実施形態をここで詳細に説明する。図面を参照すると、図面全体において、類似の番号は類似の構成要素を示す。この詳細な説明において、及び以下に続く特許請求の範囲全体において使用されるように、「a」、「an」、及び「the」の意味は、文脈上他に明確に指示されない限り、複数の参照を含む。また、この詳細な説明において、及び以下に続く特許請求の範囲全体において使用されるように、「in」の意味は、文脈上他に明確に指示されない限り、「in」及び「on」を含む。さらに、読者の便宜のために、タイトル又はサブタイトルが明細書中で使用され得る。このことは、本発明の範囲に影響を与えるものではない。加えて、この明細書において使用されるいくつかの用語が、以下により具体的に定義される。
(i)PRRSV ORF7のC末端部の2回の反復を含む抗原をコードする標的DNA。この抗原は、「DGD」又は「D」と呼ばれる。
(ii)PRRSV NSP 10(C末端ドメイン配列)及びNSP 11(N末端ドメイン配列)を融合して得られる融合抗原をコードする標的DNA。この抗原は、「M12」又は「M」と呼ばれる。
(iii)ORF6配列とORF5配列との間に架橋/リンカー配列を有しない、PRRSV ORF6のN末端部及びORF5のN末端部を融合して得られる融合抗原をコードする標的DNA。この抗原は、「RSAB」又は「R」と呼ばれる。
(iv)ORF6配列とORF5配列との間に架橋/リンカー配列を有しない、PRRSV ORF6のN末端部及びORF5のN末端部を融合して得られる融合抗原をコードする標的DNA。この抗原は、「PQAB」又は「P」と呼ばれる。
**:ボールド体の文字は、人工核輸送シグナルのアミノ酸配列を表す;下線の付された文字は、小胞体保持シグナルのアミノ酸配列を表す。
***:M(M12)は、PRRSV NSP 10(C末端ドメイン配列)及びNSP 11(N末端ドメイン配列)の融合によって調製された融合ポリペプチドである。すなわち、このポリペプチドは、非構造タンパク質であるORF1b NSP 10 C末端部及びNSP 11 N末端部に由来する。
****:P(PQAB)は、PRRSV ORF6 a.a.2−a.a.26及びORF5 aa31−aa63の融合によって調製されたポリペプチドである。米国特許第7465455号を参照。普通の文字で示される配列はPRRSV ORF6/マトリクスタンパク質配列に由来し、ボールド体の文字で示される配列はPRRSV ORF5配列に由来する。PRRSVのORF5によってコードされる主要なエンベロープタンパク質(GP5)は、ウイルス中和(VN)抗体及びPRRSVの異なる株間の交差防御の誘導において、決定的役割を有する。異なる株間には配列変異があるため、本明細書中の配列は、例示の目的で開示される。
Claims (14)
- 融合タンパク質であって、
(a)前記融合タンパク質のN末端に位置する、抗原提示細胞(APC)結合ドメインであって、前記APC結合ドメインが、シュードモナス外毒素A(PE)結合ドメインIaである、APC結合ドメイン;
(b)前記APC結合ドメインのC末端に位置する、配列番号:4、2、3、又は6と少なくとも90%同一のアミノ酸配列を含む、34−112アミノ酸残基長のトランスロケーションペプチド;
(c)以下の(i)〜(iv)を含む融合抗原;
(i)ブタ生殖器呼吸器症候群ウイルス(PRRSV)ORF7抗原;
(ii)PRRSV ORF1b抗原;
(iii)PRRSV ORF6抗原;及び
(iv)PRRSV ORF5抗原;
(d)前記融合抗原のC末端、又は前記トランスロケーションペプチドと前記融合抗原との間に位置する、配列番号:13のアミノ酸配列を含む核輸送シグナル、及び
(e)小胞体保持配列であって、前記核輸送シグナルが前記トランスロケーションペプチドと前記融合抗原との間に位置する場合は前記融合抗原のC末端に位置し、又は前記核輸送シグナルが前記融合抗原のC末端に位置する場合は前記核輸送シグナルのC末端に位置する、小胞体保持配列
を含み、
ここで、前記融合抗原が、完全長ORF7、ORF6、ORF5、及びORF1bタンパク質配列を含まず、
前記融合抗原が、
(i)配列番号:22、23又は33のアミノ酸配列;
(ii)配列番号:24のアミノ酸配列;
(iii)配列番号:25のアミノ酸配列;及び
(iv)配列番号:26のアミノ酸配列;
を含む、
融合タンパク質。 - 前記ORF7又はORF1b抗原が前記ORF6抗原のN末端に位置し、前記ORF5抗原が前記ORF6抗原のC末端に位置する、請求項1に記載の融合タンパク質。
- 前記融合抗原が、前記ORF7抗原の2つのタンデム反復を含む、請求項1に記載の融合タンパク質。
- 前記ORF5抗原が前記ORF6抗原のC末端に位置する、請求項1に記載の融合タンパク質。
- 前記ORF6抗原が、前記PRRSV ORF6のN末端部アミノ酸配列を含み、前記ORF5抗原が、前記PRRSV ORF5のN末端部アミノ酸配列を含み、前記融合抗原が、前記ORF6及びORF5のC末端部アミノ酸配列を含まない、請求項1に記載の融合タンパク質。
- 前記ORF1b抗原が、ORF1b NSP 10のC末端部アミノ酸配列及びORF1b NSP 11のN末端部アミノ酸配列を含み、前記融合抗原が、前記ORF1bのN末端及びC末端部アミノ酸配列を欠いている、請求項5に記載の融合タンパク質。
- 前記シュードモナス外毒素A(PE)結合ドメインIaが、配列番号:1又は32のアミノ酸配列を含む、請求項1に記載の融合タンパク質。
- 前記トランスロケーションペプチドが34−61アミノ酸残基長を有する、請求項1に記載の融合タンパク質。
- 前記小胞体保持配列がアミノ酸配列KDEL(配列番号:15)を含み、前記アミノ酸KDELのタンデム反復を含まない、請求項1に記載の融合タンパク質。
- 前記核輸送シグナル及び前記ER保持配列が、配列番号:12と少なくとも90%同一のアミノ酸配列と融合ペプチドを形成する、請求項9に記載の融合タンパク質。
- 前記融合タンパク質が、配列番号27又は28のアミノ酸配列を含む、請求項1〜10のいずれか一項に記載の融合タンパク質。
- 抗原特異的細胞媒介性応答及び体液性応答を、それを必要とする被験体において誘導するための組成物であって、
(i)請求項1に記載の融合タンパク質;及び
(ii)ブタサーコウイルスタイプ2(PCV2)融合タンパク質を含み、
(ii)ブタサーコウイルスタイプ2(PCV2)融合タンパク質が、
(a)前記融合タンパク質のN末端に位置する、抗原提示細胞(APC)結合ドメイン又はCD91レセプター結合ドメイン;
(b)前記APC結合ドメイン又は前記CD91レセプター結合ドメインのC末端に位置する、配列番号:4、2、3、又は6と少なくとも90%同一のアミノ酸配列を含む、34−112アミノ酸残基長のトランスロケーションペプチド;
(c)PCV2 ORF2抗原;
(d)前記PCV2 ORF2抗原のC末端、又は前記トランスロケーションペプチドと前記PCV2 ORF2抗原との間に位置する、配列番号:13のアミノ酸配列を含む核輸送シグナル;及び
(e)小胞体保持配列であって、前記核輸送シグナルが前記トランスロケーションペプチドと前記PCV2 ORF2抗原との間に位置する場合は前記PCV2融合タンパク質のC末端に位置し、又は前記核輸送シグナルが前記PCV2 ORF2抗原のC末端に位置する場合は前記核輸送シグナルのC末端に位置する、小胞体保持配列
を含み、
ここで、前記PCV2 ORF2抗原が、PCV2 ORF2タンパク質のC末端部アミノ酸配列を含み、前記PCV2融合タンパク質が、前記PCV2 ORF2タンパク質のN末端部アミノ酸配列を含まない、
組成物。 - 抗原特異的細胞媒介性応答及び体液性応答を、それを必要とする被験体において誘導するための医薬品の製造における、治療的に有効量の、請求項1〜10のいずれか一項に記載の融合タンパク質又は請求項12に記載の組成物を含む組成物の使用。
- 抗原特異的細胞媒介性応答及び体液性応答を、それを必要とする被験体において誘導するために使用される、請求項1〜10のいずれか一項に記載の融合タンパク質又は請求項12に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562169205P | 2015-06-01 | 2015-06-01 | |
US62/169,205 | 2015-06-01 | ||
PCT/US2016/034858 WO2016196383A1 (en) | 2015-06-01 | 2016-05-27 | Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018516926A JP2018516926A (ja) | 2018-06-28 |
JP6676661B2 true JP6676661B2 (ja) | 2020-04-08 |
Family
ID=57397434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017562353A Active JP6676661B2 (ja) | 2015-06-01 | 2016-05-27 | ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10010602B2 (ja) |
EP (1) | EP3302543B1 (ja) |
JP (1) | JP6676661B2 (ja) |
KR (1) | KR102041032B1 (ja) |
CN (1) | CN107847575B (ja) |
AU (1) | AU2016271144B2 (ja) |
CA (1) | CA2985381C (ja) |
DK (1) | DK3302543T3 (ja) |
ES (1) | ES2790527T3 (ja) |
TW (1) | TWI621627B (ja) |
WO (1) | WO2016196383A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
MX2017008751A (es) * | 2017-06-29 | 2019-02-08 | Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C | Proteína quimérica para la prevención y el diagnóstico del síndrome respiratorio y reproductivo porciono (prss). |
CN112105376A (zh) | 2018-03-08 | 2020-12-18 | 应用分子运输公司 | 用于经口递送的毒素衍生的递送构建体 |
CN109134667A (zh) * | 2018-09-19 | 2019-01-04 | 天康生物股份有限公司 | 融合蛋白及其制备方法、应用、表达***和疫苗 |
SG11202104734YA (en) | 2018-11-07 | 2021-06-29 | Applied Molecular Transport Inc | Cholix-derived carriers for oral delivery of heterologous payload |
CN109762047B (zh) * | 2019-02-27 | 2021-11-26 | 河南省农业科学院 | 与猪圆环病毒2型Cap蛋白特异性结合的多肽序列及其应用 |
CN110408602B (zh) * | 2019-08-02 | 2021-03-19 | 天康制药(苏州)有限公司 | Pcv2-prrsv重组病毒及其制备方法、基因、应用和疫苗 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1000163T3 (da) * | 1997-07-11 | 2006-02-06 | Us Gov Health & Human Serv | Pseudomonas-exotoksin A-lignende kimære immunogener |
US7314632B1 (en) | 1997-07-11 | 2008-01-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pseudomonas exotoxin A-like chimeric immunogens |
US20030216315A1 (en) * | 2002-02-13 | 2003-11-20 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
IL164281A0 (en) * | 2002-04-01 | 2005-12-18 | Euro Celtique Sa | Epitope constructs comprising antigen presenting cell targeting mechanisms |
US7335361B2 (en) * | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
US7595054B2 (en) * | 2003-06-09 | 2009-09-29 | Healthbanks Biotech Co., Ltd. | Fusion antigen used as vaccine |
US8206950B2 (en) * | 2003-06-09 | 2012-06-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine and method of making them |
US7596054B2 (en) | 2004-11-03 | 2009-09-29 | Drs Sustainment Systems, Inc. | Suppressed feature waveform for modulated sonar transmission |
WO2006125076A2 (en) * | 2005-05-18 | 2006-11-23 | Trinity Biosystems, Inc. | Methods and compositions for immunizing against chlamydia infection |
US7465455B2 (en) * | 2006-07-05 | 2008-12-16 | Healthbanks Biotech Co., Ltd. | Fusion protein of porcine reproductive and respiratory syndrome virus as PRRS vaccine |
CN101104641B (zh) * | 2006-07-11 | 2012-04-18 | 生宝生物科技股份有限公司 | 作为猪生殖和呼吸道征候群疫苗的prrs病毒的融合蛋白 |
EP1882478B1 (en) * | 2006-07-29 | 2012-03-21 | Healthbanks Biotech Co., Ltd. | Fusion protein of porcine reproductive and respiratory syndrome virus as PRRS vaccine |
WO2009070929A1 (fr) * | 2007-12-04 | 2009-06-11 | Schweitzer Co., Ltd. | Vaccin sous-unité pour l'aquaculture |
CA2718884C (en) * | 2008-03-20 | 2016-11-22 | University Of Miami | Heat shock protein gp96 vaccination and methods of using same |
UA113192C2 (xx) * | 2011-12-06 | 2016-12-26 | Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2) | |
US9339536B2 (en) * | 2012-12-05 | 2016-05-17 | Thevax Genetics Vaccine Co., Ltd. | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses |
-
2016
- 2016-05-27 AU AU2016271144A patent/AU2016271144B2/en active Active
- 2016-05-27 CN CN201680030712.5A patent/CN107847575B/zh active Active
- 2016-05-27 KR KR1020177037805A patent/KR102041032B1/ko active IP Right Grant
- 2016-05-27 ES ES16804176T patent/ES2790527T3/es active Active
- 2016-05-27 CA CA2985381A patent/CA2985381C/en active Active
- 2016-05-27 EP EP16804176.2A patent/EP3302543B1/en active Active
- 2016-05-27 DK DK16804176.2T patent/DK3302543T3/da active
- 2016-05-27 JP JP2017562353A patent/JP6676661B2/ja active Active
- 2016-05-27 WO PCT/US2016/034858 patent/WO2016196383A1/en active Application Filing
- 2016-05-27 US US15/167,911 patent/US10010602B2/en active Active
- 2016-05-31 TW TW105117088A patent/TWI621627B/zh active
Also Published As
Publication number | Publication date |
---|---|
WO2016196383A1 (en) | 2016-12-08 |
EP3302543A1 (en) | 2018-04-11 |
JP2018516926A (ja) | 2018-06-28 |
EP3302543A4 (en) | 2018-12-05 |
CA2985381C (en) | 2020-03-24 |
DK3302543T3 (da) | 2020-05-18 |
CA2985381A1 (en) | 2016-12-08 |
KR102041032B1 (ko) | 2019-11-27 |
CN107847575B (zh) | 2021-12-17 |
ES2790527T3 (es) | 2020-10-28 |
TWI621627B (zh) | 2018-04-21 |
US10010602B2 (en) | 2018-07-03 |
CN107847575A (zh) | 2018-03-27 |
US20160346377A1 (en) | 2016-12-01 |
EP3302543B1 (en) | 2020-04-29 |
AU2016271144B2 (en) | 2018-10-25 |
KR20180015185A (ko) | 2018-02-12 |
AU2016271144A1 (en) | 2017-11-30 |
TW201706296A (zh) | 2017-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6449384B2 (ja) | 抗原特異的t細胞反応を誘導するための免疫原エンハンサーとしての融合タンパク質 | |
JP6676661B2 (ja) | ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物 | |
Denis et al. | Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization | |
JP6535133B2 (ja) | 新規のバキュロウイルスベクター及び使用の方法 | |
Wang et al. | Immunogenicity of a bovine viral diarrhea virus E2–C3d fusion protein containing a bovine homolog of C3d | |
Ge et al. | Fusion expression of major antigenic segment of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70 | |
Harakuni et al. | Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171219 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190716 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191015 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200310 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200312 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6676661 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |